– Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment – “Today's approval reflects our ...

The US Food and Drug Administration (FDA) has approved omalizumab injection (Xolair, Genentech) for children aged 1 year or older and adults to reduce immunoglobulin E─mediated severe allergy to ...

EAST HANOVER, N.J., April 12, 2021 /PRNewswire/ — Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair (R) ...

A medication used to treat asthma can now be used to help people with food allergies avoid severe reactions, the U.S. Food and Drug Administration said Friday. Xolair, the brand name for the drug ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a self-injectable formulation of Xolair for appropriate patients with moderate to severe ...

A recent review paper published in Current Opinion in Allergy and Clinical Immunology suggests that when combined with allergen immunotherapy the biologic omalizumab (Xolair) can enhance efficacy and ...

A new drug could let those with severe food allergies breathe a sigh of relief. Xolair, or omalizumab, was granted priority review by the Food and Drug Administration on Tuesday for its use in ...

Xolair, an antibody asthma drug, was recently approved for severe food allergic reactions. It is not the first biological drug to treat multiple conditions. But it is the first to treat severe food ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

(RTTNews) - Roche (RHHBY) said Tuesday that it has received an approval from the U.S. Food and Drug Administration for its supplemental Biologics License Application of Xolair or omalizumab prefilled ...